[Indications and follow-up for autologous hematopoietic stem cell transplantation in multiple sclerosis: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC) in association with the Francophone Society of Multiple Sclerosis].
rge D Abstract The Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC) organized the 8th allogeneic hematopoietic stem cell transplantation clinical practices harmonization workshop series in September 2017 in Lille, France. In this article we give the indications of autologous stem cell transplantation in multiple sclerosis as well as recommendations regarding post-transplant follow-up of patients under the hospice of the SFGM-TC and the Francophone Society of Multiple Sclerosis. PMID: 30527815 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - December 4, 2018 Category: Cancer & Oncology Authors: Zephir H, Puyade M, Gueguen A, Michel L, Terriou L, Dive D, Laureys G, Mathey G, Labauge P, Marjanovic Z, Pugnet G, Badoglio M, Lansiaux P, Ibrahim YA, Béguin Y, Farge D Tags: Bull Cancer Source Type: research

[Lynch syndrome: What is new?]
te; T Abstract Lynch syndrome is a genetic condition defined by a germline mutation of an MMR (MisMatch Repair) gene leading to a defective DNA MMR system. Therefore, it is characterized by the predisposition to a spectrum of cancers, primarily colorectal cancer (CRC) and endometrial cancer (EC). Lynch syndrome-related CRC accounts for 3% of all CRC. Lynch syndrome also accounts for 2% of all EC. In case of Lynch syndrome, there is usually a familial history of cancer defined by the Amsterdam and Bethesda criteria. Diagnosis is made by tumor testing with (i) MMR immunohistochemistry and (ii) PCR for MSI (microsate...
Source: Bulletin du Cancer - December 4, 2018 Category: Cancer & Oncology Authors: Pellat A, Netter J, Perkins G, Cohen R, Coulet F, Parc Y, Svrcek M, Duval A, André T Tags: Bull Cancer Source Type: research

[Epithelioid hemangioendothelioma].
We describe herein the inaugural manifestations, the radiological and histological diagnosis criteria for and the outcome of epithelioid hemangioendothelioma (EHE). Most of EHE (90%) display a specific reciprocal chromosomic translocation t(1;3)(p36;q23-25), which is associated with the synthesis of fusion protein WWTR1/CAMTA1. EHE are low-grade vascular sarcomas. EHE could be initially localized or multifocal. At localized stage, EHE are best treated with focal treatments. At multifocal stage, the upfront strategy is watchful follow-up. Some multifocal EHE display very indolent course with spontaneous stable disease for y...
Source: Bulletin du Cancer - December 4, 2018 Category: Cancer & Oncology Authors: Cousin S, Le Loarer F, Crombé A, Karanian M, Minard-Colin V, Penel N Tags: Bull Cancer Source Type: research

Bibliometrics and French healthcare institutions from 2004 to 2014.
This study also found that public non-teaching hospitals, not-for-profit private hospitals, for-profit private hospitals, and cancer centres collaborated with other institutions which were often distinguished by publishing in high-category journals. PMID: 30509682 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - November 30, 2018 Category: Cancer & Oncology Authors: Blanc E, Boulieu R, Bertram D Tags: Bull Cancer Source Type: research

[Efficacy and toxicity of immune checkpoint inhibitors in elderly patients - 5th edition of the congress of pharmacology of anticancer drugs].
Abstract Physiological aging causes qualitative or quantitative immune system decline, also called immunosenescence. Older people with cancer are often ineligible for chemotherapy. The new immunotherapies (with PD1, PDL1 and CTLA4 checkpoint inhibitors) have proven their effectiveness in many tumor types regardless of age and are often better tolerated than chemotherapy. In the older population, the subgroup data from the different pivotal studies show fairly reassuring efficacy and safety data, despite the frequent lack of power given the small population included. There remains, however, some doubt that age may ...
Source: Bulletin du Cancer - November 21, 2018 Category: Cancer & Oncology Authors: Gaultier De Saint Basile H, Poisson C, Arrondeau J, Boudou-Rouquette P, Goldwasser F, Tartour E, De Guillebon E Tags: Bull Cancer Source Type: research

[Subcutaneous administration of trastuzumab at home: Feedback of patients treated in 2016 by Sant é service].
This study aims to assess the experience of patients treated by trastuzumab subcutaneously at home in 2016, and the experience of the nurses who performed these injections. In 2017, a retrospective survey by phone calls could gather the impressions from 84 patients on their treatment. And 60 nurses answered to a written survey. The whole treatment session is estimated to last 30minutes to one hour by most of the patients (60%) and the nurses (85%), with an injection duration below 5 minutes (according to 71% of patients and 77% of nurses). The main side effects described were: rash (reported by 40% of patients and 52%...
Source: Bulletin du Cancer - November 19, 2018 Category: Cancer & Oncology Authors: Pailler C, Chapot T, Softa S, Gandrille N, Ruiz D, Mathieu S, Delaloge S Tags: Bull Cancer Source Type: research

[Prostate cancer screening: Reasons of controversy].
Abstract We propose herein a short synthesis of evidence leading to deny organized screening of prostate cancer using PSA plus or minus rectal digital examination. Nevertheless, many scientific societies support opportunistic screening on basis of shared decision. Today, numerous proposals had been made to reduce the overdiagnosis and overtreatreatment. PMID: 30458966 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - November 17, 2018 Category: Cancer & Oncology Authors: Delporte G, Villers A, Penel N Tags: Bull Cancer Source Type: research

[Clinical pharmacy in a bone marrow and cellular therapy transplantation ward-which methods to put in place: Guidelines from the francophone Society of bone marrow transplantation and cellular therapy (SFGM-TC)].
Abstract Since, several years the integration of a clinical pharmacist in medical units led to improve the patients' care in France. In the frame of stem cell engraftment, patients belong to a particularly complex population, notably due to pediatric patients or because the age to engraft adult patients is higher. Moreover, because of many reasons, such as numerous medications intake or long-term immunosuppression, these patients are very fragile and at risk of complications. Since the 6th edition, the JACIE standard gives a definition of the role of clinical pharmacist with its competence area and its place in th...
Source: Bulletin du Cancer - November 16, 2018 Category: Cancer & Oncology Authors: Forcade E, Bonnin A, Desoutter J, Nacimento F, Roch-Torreilles I, Vigneron F, Boiron JM, Yakoub-Agha I, Simon N Tags: Bull Cancer Source Type: research

[Harmonization of data coding in post-transplant follow-up - "GVHD, complications and additional treatments": Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].
The objective of this workshop was to clarify certain situations and/or items. PMID: 30448095 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - November 15, 2018 Category: Cancer & Oncology Authors: Cornillon J, Detrait M, Karam M, Le Bars L, Meziane Y, Pereira M, Richard-Leveille S, Marion S, Leroux S, Coiteux V, Raus N, Seris S, Guyotat D, Yakoub-Agha I, Laurent N Tags: Bull Cancer Source Type: research

[Development of a standardized guide for optimizing drug adherence information to be dispensed during a pharmaceutical counseling with a multiple myeloma patient: Final validation].
This study led to the final validation of the pharmaceutical counselling guide. PMID: 30446157 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - November 13, 2018 Category: Cancer & Oncology Authors: Favier-Archinard C, Leguelinel-Blache G, Cousin C, Gillet C, Bourquard P, Dubois F, Passemard N, Tora S, Rey A, Heraut B, Chevallier T, Favier M Tags: Bull Cancer Source Type: research

[Second allogeneic hematopoietic stem cell transplant: Guidelines from the francophone Society of bone marrow transplantation and cellular therapy (SFGM-TC)].
te; X Abstract Disease recurrence and graft dysfunction after allogeneic hematopoietic stem cell transplantation (allo-HSCT) currently remain among the major causes of treatment failure in malignant and non-malignant hematological diseases. A second allo-HSCT is a valuable therapeutic option to salvage those situations. During the 8th annual harmonization workshops of the french Society of bone marrow transplantation and cellular therapy (SFGM-TC), a designated working group reviewed the literature in order to elaborate unified guidelines on feasibility, indications, donor choice and conditioning in the case of a ...
Source: Bulletin du Cancer - November 5, 2018 Category: Cancer & Oncology Authors: Yafour N, Couturier MA, Azarnoush S, Girault S, Hermet E, Masouridi Levrat S, Schmidt A, Michallet M, Etancelin P, Guillaume T, Malard F, Sirvent A, Yakoub-Agha I, Poiré X Tags: Bull Cancer Source Type: research

[Epidemiology of microsatellite instability across solid neoplasms].
Abstract Microsatellite instability (MSI) is a predictive biomarker for the efficacy of immune checkpoint inhibitors, regardless of the tumor type. While clinical characteristics of MSI cancer patients have been largely described in tumor localizations frequently associated with this genetic phenotype (i.e. colorectal cancer, endometrial cancer), it remains poorly characterized in other neoplasms. Pan-tumor high-throughput genome sequence analyses have contributed to the broadening of knowledge about the landscape of MSI. This review aims at synthetizing the literature concerning the frequency of MSI status in sol...
Source: Bulletin du Cancer - November 5, 2018 Category: Cancer & Oncology Authors: Colle R, Cohen R Tags: Bull Cancer Source Type: research

[Evaluation of management disparity in patients with chronic lymphocytic leukemia in France].
Abstract Environmental factors have an impact on the effectiveness of treatments for chronic lymphocytic leukemia: vulnerability, organization of the supply of care and proximity of the patient to health professionals. The disparity of care was assessed; vulnerability by the European index of deprivation, the provision of care by values of localized potential accessibility to general practitioners, nurses and pharmacists and hospital supply by the density of hematologists and time access to the center. The data, extracted from the public databases for each grouped island for statistical information, were cross-ref...
Source: Bulletin du Cancer - November 2, 2018 Category: Cancer & Oncology Authors: Rateau Y, Harbouche M, Damaj G, Troussard X Tags: Bull Cancer Source Type: research

[Epidemiological, clinical, histological and therapeutic features of primary digestive cancers in Burkina Faso].
CONCLUSION: In Burkina Faso rural area, primary digestive cancers occur in young patients with no predominance of sex. Colorectal cancer remains the most common. PMID: 30392708 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - November 1, 2018 Category: Cancer & Oncology Authors: Ouedraogo S, Ouedraogo S, Kambire JL, Zoungrana SL, Ouattara DZ, Bambara B, Traore MT Tags: Bull Cancer Source Type: research

[Post-transplant neurological complications: Guidelines from the francophone Society of bone marrow transplantation and cellular therapy (SFGM-TC)].
Abstract Neurological complications post-allogeneic hematopoietic stem cell transplantation are well-characterized; however, given their variable impact, they remain a significant cause of morbidity. The etiologies for these complications are vast. Causes may be linked to toxicity and infection or could be vascular or tumor-related. Regardless, these complications require early investigation, which is often multidisciplinary and hierarchical. Preventive measures may be considered in some situations. It is essential to respond early and quickly with a diagnosis and the appropriate therapeutic approach when faced wi...
Source: Bulletin du Cancer - November 1, 2018 Category: Cancer & Oncology Authors: Hicheri Y, Buchbinder N, Magro L, Farah B, Zephir H, Brissot E, Yakoub-Agha I, Chevallier P Tags: Bull Cancer Source Type: research

[Prevalence of pain in radiotherapy and improvement of its management].
CONCLUSIONS: This study confirms the importance, the underestimation and undertreatment, of pain management in radiotherapy departments. We recommend using a standardised questionnaire to identify patients at highest risk of pain, and the use of specialised pain relief teams when needed. A radiation therapist could act as a referrer to the pain relief team. Pain management remains teamwork, with links to specialised units. PMID: 30366592 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - October 23, 2018 Category: Cancer & Oncology Authors: Dantigny R, Tanty A, Fourneret P, Genin N, Bayet-Papin B, Mousseau M, Hau Desbat NH Tags: Bull Cancer Source Type: research

Why is immunotherapy effective (or not) in patients with MSI/MMRD tumors?
Abstract In the last few years, immunotherapy has revolutionized the oncology landscape by targeting the host immune system. Blocking immune checkpoints such as cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), programmed cell death-1 (PD-1) and its ligand (PD-L1 or B7-H1), has proven its efficacy in several solid cancers. Recently, several clinical studies have demonstrated a significant improvement in clinical response to the anti-PD-1-based immunotherapy in a subset of patients with microsatellite instability-high (MSI-H)/mismatch repair (MMR)-deficient tumors that accumulate short insertion/deletion mutati...
Source: Bulletin du Cancer - October 17, 2018 Category: Cancer & Oncology Authors: Nebot-Bral L, Coutzac C, Kannouche PL, Chaput N Tags: Bull Cancer Source Type: research

[Hot topics about early clinical trials at ASCO congress 2018: News pathways, new targets, new associations].
Abstract Looking at the results of the early trials presented at the 2018 American Society of Clinical Oncology (ASCO) conference can help identify the molecules and strategies that will potentially enter the practices of tomorrow. It is in this spirit that this subject has justified the attention of residents in oncology and the writing of this synthesis. Molecules that can represent breakthrough innovations are presented as well as new therapeutics under development acting on targets already validated in clinical practice and early data of checkpoint inhibitors in combination with different immunomodulators, as ...
Source: Bulletin du Cancer - October 16, 2018 Category: Cancer & Oncology Authors: Auvray M, Baylot C, Blanc-Durand F, Borcoman E, Pons-Tostivint E, Vignot S Tags: Bull Cancer Source Type: research

[Cytoreduction nephrectomy: No future?]
PMID: 30336932 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - October 15, 2018 Category: Cancer & Oncology Authors: Balssa L, Kleinclauss F, Almotlak H, Thiery-Vuillemin A Tags: Bull Cancer Source Type: research

Immunotherapy and metastatic colorectal cancers with microsatellite instability or mismatch repair deficiency.
te; T Abstract Microsatellite instability (MSI) is a molecular indicator of defective DNA mismatch repair (dMMR) and is observed in approximately 5% of metastatic colorectal cancers (mCRC). MSI is a major predictive biomarker for the efficacy of immune checkpoint inhibitors (ICKi) amongst mCRC patients. After summarizing the literature about the efficacy of conventional cytotoxic regimens, we will highlight studies that have demonstrated the clinical activity of ICKi for patients with chemoresistant MSI/dMMR mCRC. Then we will focus on ongoing clinical trials and emerging challenges for the treatment of patients w...
Source: Bulletin du Cancer - October 13, 2018 Category: Cancer & Oncology Authors: Cohen R, Pellat A, Boussion H, Svrcek M, Lopez-Trabada D, Trouilloud I, Afchain P, André T Tags: Bull Cancer Source Type: research

[Elaboration and evaluation of a therapeutic education program in cancer pain management].
This article aims to present the program which originality and strengths are based on collaborative work between health stakeholders. Objectives, methodology and expected results of the research phase (stages 2, 4, 5) are notably developed. The main expected outcomes are to prove the effectiveness of the program in improving the knowledge and skills of patients in the field of pain cancer in order to promote their adherence to treatment and, consequently, to enable them to better manage it. The long-term objective is to disseminate the educational approach by modifying practices that provide a mutual benefit for caregivers...
Source: Bulletin du Cancer - October 13, 2018 Category: Cancer & Oncology Authors: Prevost V, Clarisse B, Heutte N, Leconte A, Bisson C, Bignon R, Cauchin S, Feuillet M, Gehanne S, Gicquère M, Grach MC, Guillaumé C, Le Gal C, Le Garrec J, Lecaer F, Lepleux I, Millet AL, Ropartz MC, Roux N, Sep Hieng V, Van Delook C, Bechet C, Le Cheva Tags: Bull Cancer Source Type: research

Totally implanted venous access-associated adverse events in oncology: Results from a prospective 1-year surveillance programme.
We report accurate estimations of TIVA-AE incidences in one of the largest populations among previously published studies. As in previous studies, metastatic cancers and hematologic malignancies tended to be associated with a higher risk of infectious TIVA-AE. Further studies are warranted to confirm the effect of digestive cancers. PMID: 30322697 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - October 12, 2018 Category: Cancer & Oncology Authors: Vermeulin T, Lucas M, Marini H, Di Fiore F, Loeb A, Lottin M, Daubert H, Gray C, Guisier F, Sefrioui D, Michel P, de Mil R, Czernichow P, Merle V Tags: Bull Cancer Source Type: research

PTBP1 promotes tumorigenesis by regulating apoptosis and cell cycle in colon cancer.
This study implies that PTBP1 plays an important role in tumorigenesis of colon cancer. PMID: 30309622 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - October 8, 2018 Category: Cancer & Oncology Authors: Li X, Han F, Liu W, Shi X Tags: Bull Cancer Source Type: research

[Issues of oral targeted therapies in daily clinical practice: 5th edition of the congress of pharmacology of anticancer drugs].
Abstract Oral targeted therapies are a growing class of medication. After clinical trials conducted on a selected population, these molecules are usually approved at a fixed dose. However, oral tyrosine kinase inhibitors are characterized by a large intra and inter-individual pharmacokinetic variability, and a narrow therapeutic index. Hence, their prescription is hazardous and unsafe in non-selected people from daily clinical practice. The increasing number of available targeted therapies point out new challenges. These challenges should especially concern prescription for out of the ordinary patients, rules for ...
Source: Bulletin du Cancer - October 8, 2018 Category: Cancer & Oncology Authors: Zaibet S, Vauchier C, Khoudour N, Roulleaux Dugage M, Korb-Savoldelli V, Alexandre J, Blanchet B, Goldwasser F, Thomas-Schoemann A, Bellesoeur A Tags: Bull Cancer Source Type: research

Bevacizumab: Is the lower the better for glioblastoma patients in progression?
DISCUSSION: Use of bevacizumab at progression at lower than usual doses seems to give the same results as the standard dose without giving additional toxicity. PMID: 30301554 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - October 6, 2018 Category: Cancer & Oncology Authors: Sirven-Villaros L, Bourg V, Suissa L, Mondot L, Almairac F, Fontaine D, Paquis P, Burel-VandenBos F, Frenay M, Thomas P, Lebrun-Frenay C Tags: Bull Cancer Source Type: research

[Dermatofibrosarcoma: Management].
Abstract Dematofibrosarcoma protuberans (DFSP) are very rare (1 to 4 incident cases per million of inhabitants). The local spreading of DFSP is underestimated. The histological diagnosis is challenging but we now know a specific marker (translocation t(17;22)(q22;q13) (COL1A1;PDGFB)). The risk of metastatic relapse is low (and related to fibrosarcoma component); the risk of local relapse depends on the quality of surgery. Management of localized DFSP is based on large resection with meticulous analysis of margins (with or without Mohs microsurgery). Advanced stages not amenable to surgery or metastatic DFSP (with ...
Source: Bulletin du Cancer - October 5, 2018 Category: Cancer & Oncology Authors: Penel N, El Bedoui S, Robin YM, Decanter G Tags: Bull Cancer Source Type: research

[High-risk neuroblastoma treatment strategy: The experience of the SIOPEN group].
Abstract High-risk neuroblastoma comprises nearly half of cases of neuroblastoma and the long-term survival is less than 50% despite complex and intensive treatments. Studies conducted in Europe and in North America in the last two decades have identified a strategy based on four therapeutic phases: an intensive induction therapy, a local control by surgery and radiation, a consolidation phase with single or tandem high dose chemotherapy and autologous transplant, and immunotherapy to eliminate residual disease. Future treatment improvements are based on progress at each of these therapeutic steps and ultimately a...
Source: Bulletin du Cancer - October 2, 2018 Category: Cancer & Oncology Authors: Valteau-Couanet D, Schleiermacher G, Sarnacki S, Pasqualini C Tags: Bull Cancer Source Type: research

Consumption of processed and pickled food and esophageal cancer risk: A systematic review and meta-analysis.
In conclusion, this study suggests that both a high consumption of processed and pickled food may increase the EC risk. PMID: 30290976 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - October 2, 2018 Category: Cancer & Oncology Authors: Yan B, Zhang L, Shao Z Tags: Bull Cancer Source Type: research

[DNA damage repair: An emerging strategy in metastatic prostate cancer].
Abstract Genetic instability is one part of the oncogenic process. Gene mutations involved in DNA repair mechanisms can promote this genetic instability and participate in oncogenesis and metastatic progression. In prostate cancer, DNA repair abnormalities mainly correspond to somatic or constitutional mutations of the BRCA2 and ATM genes. Therapeutic management of metastatic castration-resistant prostate cancer (mCRPC) is currently based on new hormonal therapies (abiraterone, enzalutamide) and taxane-type chemotherapy (docetaxel or cabazitaxel). Preliminary data tend to indicate a specific activity of agents cau...
Source: Bulletin du Cancer - September 29, 2018 Category: Cancer & Oncology Authors: Loriot Y, Meynard G, Klajer E, Bolognini C, Gassian N, Thiery-Vuillemin A Tags: Bull Cancer Source Type: research

[Opioid switch and change of route of administration in cancer patients treated by morphine].
Abstract This paper reviewed the 2002 guidelines established by the National Federation of Cancer Centres. A group of experts nominated by the 3 French Societies involved in the treatment of cancer pain (AFSOS, SFAP, SFETD), established new guidelines ratios for morphine switching and/or changing of route of administration, in patients for whom either pain was not adequatly managed or adverse effects were unbearable. After a rapid reminder of the pharmacokinetics and metabolism properties of morphine, experts explained why the theory of opioid rotation (oxycodone, hydromorphone, fentanyl, methadone, tape...
Source: Bulletin du Cancer - September 28, 2018 Category: Cancer & Oncology Authors: Michenot N, Rostaing S, Baron L, Faure S, Jovenin N, Hubault P, Delorme T, Collin E, Filbet M, Chvetzoff G, Delorme C, Minello C, Magnet M, Ammar D, Krakowski I, Poulain P Tags: Bull Cancer Source Type: research

Bladder cancer knowledge in the Lebanese population: When ignorance could be harmful.
This study was designed to assess bladder cancer knowledge among the Lebanese population. Between November 2017 and January 2018, a cross-sectional study was directed, including patients and visitors of one of the largest university hospitals in the capital Beirut. A face-to-face questionnaire evaluated knowledge regarding, among others, the most important risk factor for bladder cancer and the most frequent revealing symptom. This survey also obtained information regarding smoking habits. A total of 701 participants completed the survey. A total of 49.1% were younger than 50 years, 56.3% were male, 56.6% had a college deg...
Source: Bulletin du Cancer - September 26, 2018 Category: Cancer & Oncology Authors: Souaid T, Hindy JR, Eid R, Kourie HR, Kattan J Tags: Bull Cancer Source Type: research

[The French Genetic and Cancer Consortium guidelines for multigene panel analysis in hereditary breast and ovarian cancer predisposition].
DISCUSSION: Due to the rapid increase in knowledge, the GGC has planned a yearly update of the bibliography to take into account new findings. Furthermore, genetic-epidemiological studies are being initiated to better estimate the cancer risk associated with genes which are not yet included in the HBOC diagnosis panel. PMID: 30268633 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - September 26, 2018 Category: Cancer & Oncology Authors: Moretta J, Berthet P, Bonadona V, Caron O, Cohen-Haguenauer O, Colas C, Corsini C, Cusin V, De Pauw A, Delnatte C, Dussart S, Jamain C, Longy M, Luporsi E, Maugard C, Nguyen TD, Pujol P, Vaur D, Andrieu N, Lasset C, Noguès C, Groupe génétique et cancer Tags: Bull Cancer Source Type: research

Knockdown of miR-299-5p inhibits the progression of hepatocellular carcinoma by targeting SIAH1.
CONCLUSIONS: MiR-299-5p knockdown suppressed the progression of HCC by targeting SIAH1, highlighting its role as a potential biomarker and therapeutic target of HCC. PMID: 30266288 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - September 25, 2018 Category: Cancer & Oncology Authors: Jiang X, Shen X Tags: Bull Cancer Source Type: research

[Data from the AACR 2018 meeting on the combination chimio-immunotherapy on advanced non-small cells lung cancer (NSCLC)].
lez M PMID: 30262415 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - September 24, 2018 Category: Cancer & Oncology Authors: Simonneau Y, Ruppert AM, Chaabane N, Lavolé A, Wislez M Tags: Bull Cancer Source Type: research

[Chemotherapy-induced peripheral neuropathy: Symptomatology and epidemiology].
lla V Abstract Chemotherapy-induced peripheral neuropathy (CIPN) is common with specific semiological characteristics. When CIPN appears, there are many difficulties in guaranteeing sustained treatment, especially with optimal protocol. Moreover, CIPN have bad repercussions on quality of life after cancer disease. In this article, we have achieved a current state of CIPN and try to report details about semiological characteristics and topography. We have also produced some epidemiological data. Nonetheless, we have not voluntarily introduced treatment because it will be the topic of further work. PMID: 302449...
Source: Bulletin du Cancer - September 20, 2018 Category: Cancer & Oncology Authors: Kerckhove N, Collin A, Condé S, Chaleteix C, Pezet D, Balayssac D, Guastella V Tags: Bull Cancer Source Type: research

[Physiopathological mechanisms of immune-related adverse events induced by anti-CTLA-4, anti-PD-1 and anti-PD-L1 antibodies in cancer treatment].
Abstract Recently, the emergence of anti-CTLA-4 and anti-PD-1/PD-L1 antibodies called immune check-point inhibitors (ICPI) has modified the landscape of anti-cancer treatments. These therapeutics are associated with immune related adverse events that affect many organs, most commonly skin, digestive tract, endocrine glands and lungs. This review summarizes the main physiopathological hypotheses on the mechanisms of these toxicities. In most cases, the T lymphocytes hyperactivation induced by ICPI generates a specific response directed against tumor antigens, leading to anti-tumor activity in tumor tissues but also...
Source: Bulletin du Cancer - September 20, 2018 Category: Cancer & Oncology Authors: Passat T, Touchefeu Y, Gervois N, Jarry A, Bossard C, Bennouna J Tags: Bull Cancer Source Type: research

[Medico-economic benefits of subcutaneous formulations of trastuzumab and rituximab in day hospitalisation (SCuBA Study)].
The objective of this study was to evaluate the medical and economic consequences of switching to subcutaneous formulations of trastuzumab and rituximab. METHODS: Thirty-six day care units in 30 hospitals or clinics participated in this observational study. Data were collected on the capacity of the units, the number of chemotherapy sessions implemented, the duration of occupation of a chair and the production capacity of the unit pharmacy. The number of additional sessions made possible by the use of subcutaneous forms in 2016 was determined and the associated gain in earnings calculated using national tariffs. ...
Source: Bulletin du Cancer - September 20, 2018 Category: Cancer & Oncology Authors: Favier M, Le Goc-Sager F, Vincent-Cantini I, Launay V, Giroux EA, Lièvremont K, Bonnet I, Barbe C, Duval E, Loric N, Delbaldo C Tags: Bull Cancer Source Type: research

[Le Bulletin du Cancer: Developing adult - children partnership].
PMID: 30243476 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - September 19, 2018 Category: Cancer & Oncology Authors: Gandemer V, Orbach D, Pellier I Tags: Bull Cancer Source Type: research

[Minimal residual disease in chronic lymphocytic leukemia: A still current issue in 2018].
Abstract Minimal residual disease (MRD) is widely used in oncohematology. In chronic lymphocytic leukemia (CLL), it can be measured by flow cytometry or polymerase chain reaction and is getting a greater place, owing to the dramatic therapeutic advances in the management this disease. As MRD decrease after chemoimmunotherapy is associated with improved progression free and overall survivals, its measure is now recommended as a surrogate marker for cytotoxic drugs licensures. This association is independent from treatment received and raises a few questions, such as sequential MRD measures to stop treatment in case...
Source: Bulletin du Cancer - September 19, 2018 Category: Cancer & Oncology Authors: Gauthier M, Comont T, Vergez F, Ysebaert L Tags: Bull Cancer Source Type: research

Precision medicine and bladder cancer heterogeneity.
Abstract Bladder cancer is a widespread and highly heterogeneous malignancy. Moreover, bladder cancer recurrence and treatment failure are common, making this disease a challenge for genito-urinary surgeons. Precision medicine represents a new medical concept and model. It is based on personalized medicine, and employs genomics, proteomics, and other omics and cutting-edge medical technologies to classify disease at the molecular level, enabling accurate identification of its cause and therapeutic targets, ultimately offering precise, personalized medicine. The existence of heterogeneity in bladder cancer, resulti...
Source: Bulletin du Cancer - September 19, 2018 Category: Cancer & Oncology Authors: Ma G, Yang X, Liang Y, Wang L, Li D, Chen Y, Liang Z, Wang Y, Niu H Tags: Bull Cancer Source Type: research

[How to predict the relapse after surgery or radiofrequency of liver metastases of colorectal cancer? Interest of the serum kinetic variation of a matrix metalloproteinase cluster].
CONCLUSION: This is the first study wich correlates the post-operative level of 4 MMPs and TIMP-1 with the risk of liver recurrence after surgery or radiofrequency. Serum TIMP-1 level at J0 could be helpful to identify patients with higher risk but these results need to be confirmed in a large-scale study. PMID: 30243479 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - September 19, 2018 Category: Cancer & Oncology Authors: Frenoux C, Rebischung C, Quesada JL, Mendosa C, Letoublon C, Trocmé C Tags: Bull Cancer Source Type: research

[Metastatic stomach cancer: Clinical trials in Asia and in Occident].
Abstract Although cytotoxic chemotherapy is the main therapeutic option to treat gastric cancer in the metastatic setting, molecular targeted agents have recently been introduced in an effort to improve survival outcomes which in average do not exceed 1 year. Trastuzumab and ramucirumab, antibodies directed against HER2 and VEGFR2, respectively, may provide clinical benefit for some patients. Results of clinical studies show that Asian patients have increased survival compared to Caucasian patients. Differences between populations, and in particular the presence of polymorphisms capable of influencing the ava...
Source: Bulletin du Cancer - September 19, 2018 Category: Cancer & Oncology Authors: Bui QL, Grazziotin-Soares D, Hasiniatsy RE, Trinh HS, Richard S, Lotz JP, Gligorov J, Khalil A Tags: Bull Cancer Source Type: research

[Adjuvant chemotherapy for upper tract urothelial cancer: Level of evidence IA].
PMID: 30236478 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - September 17, 2018 Category: Cancer & Oncology Authors: Pannier D, Fantoni JC, Turpin A, Penel N Tags: Bull Cancer Source Type: research

[CAR T cells: Current indications in children and perspectives].
hel A Abstract Acute lymphoblastic leukemia (ALL) is the first cause of cancer in children. Five-year overall survival is greater than 90% but leukemia remains a major cause of death from cancer in children. A new class of immunotherapy based on a chimeric antigen receptor "CAR" targeting the CD19 on the B leukemic cells and that is transduced in an autologous or allogenic T lymphocyte will allow to transform the prognosis of refractory or relapsed B-ALL. Overall response rates range from 60 to 90% in phase I-II studies in patients with second relapse or more or with refractory disease. Persistent remiss...
Source: Bulletin du Cancer - September 17, 2018 Category: Cancer & Oncology Authors: Dourthe MÉ, Yakouben K, Chaillou D, Lesprit E, Dalle JH, Baruchel A Tags: Bull Cancer Source Type: research

[Management of uveal melanomas, guidelines for oncologists].
Abstract Uveal melanomas are the most frequent primary malignant eye tumor. Enucleation was historically the gold standard. Since then, several studies showed that conservative treatments did not increase the risk of metastasis or survival. Choroidal melanomas are both radioresistant and located close to visual structures (the optic nerve and macula) of the eye, which may be preserved in some settings without compromising tumor control, as this is the first priority. Different types of radiation therapy may be used for such tumors: brachytherapy and charged particles, including proton beam therapy. If visual progn...
Source: Bulletin du Cancer - September 11, 2018 Category: Cancer & Oncology Authors: Mathis T, Cassoux N, Tardy M, Piperno S, Gastaud L, Dendale R, Maschi C, Nguyen AM, Meyer L, Bonnin N, Baillif S, Tick S, Mouriaux F, Jaspart F, Dellis J, Rosier L, Desjardins L, Herault J, Caujolle JP, Thariat J Tags: Bull Cancer Source Type: research

[Smoking and alcohol cessation programs in patients with head and neck cancer].
er Denois V Abstract Most head and neck cancers are associated with smoking and alcohol exposure. Smoking and alcohol cessation (ASC) is associated with improved quality of life, cancer therapy efficacy, decreased treatment-related and cardiovascular risks, and is expected to decrease the risk of second primary tumor. It is therefore a high priority in the plan of care. However, results of current ASC programs are disappointing and understanding the reasons of this is critical. We started a qualitative study in 6 academic centers including 3 university hospitals, one regional hospital and one comprehensive cancer ...
Source: Bulletin du Cancer - September 7, 2018 Category: Cancer & Oncology Authors: Hamant C, Deneuve S, Albaret MA, Zrounba P, Breton P, Céruse P, Gleizal A, Alix T, Bettega G, Chauvin F, Saintigny P, Régnier Denois V Tags: Bull Cancer Source Type: research

[Autopsy of an expert consensus. To end hyperthermic intraperitoneal chemotherapy in colorectal carcinomatosis].
PMID: 30173868 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - August 30, 2018 Category: Cancer & Oncology Authors: Evrard S Tags: Bull Cancer Source Type: research

[Genealogy of lymph node and visceral metastases in colorectal cancer: "sisters" or "cousins"?]
[Genealogy of lymph node and visceral metastases in colorectal cancer: "sisters" or "cousins"?] Bull Cancer. 2018 Aug 24;: Authors: Vibert J, Rousseau B PMID: 30149945 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - August 24, 2018 Category: Cancer & Oncology Authors: Vibert J, Rousseau B Tags: Bull Cancer Source Type: research

[How to manipulate DNA repair to generate neoantigens and ameliorate the efficacy of immunotherapies].
PMID: 30146085 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - August 23, 2018 Category: Cancer & Oncology Authors: Pourquier P Tags: Bull Cancer Source Type: research

[Adaptive designs for innovative therapies assessment: New methodological challenges].
PMID: 30146086 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - August 23, 2018 Category: Cancer & Oncology Authors: Asselain B Tags: Bull Cancer Source Type: research